Patents by Inventor Jasdeep MANN

Jasdeep MANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20240301018
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: February 22, 2024
    Publication date: September 12, 2024
    Applicant: 2seventy bio, Inc.
    Inventors: Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
  • PD-1 homing endonuclease variants, compositions, and methods of use
    Patent number: 11912746
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: February 27, 2024
    Assignee: 2seventy bio, Inc.
    Inventors: Jasdeep Mann, Joel Gay, Jordan Jarjour, Joy Zhang
  • MAGE A4 T CELL RECEPTORS
    Publication number: 20230159612
    Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 25, 2023
    Inventors: Christian ELLINGER, Daniel SOMMERMEYER, Geoffrey PARSONS, Jasdeep MANN
  • T CELL RECEPTORS
    Publication number: 20230124640
    Abstract: The present disclosure provides improved T cell receptors, polynucleotides, polypeptides, vectors, cells, and methods f using the same.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 20, 2023
    Applicant: 2seventy bio, Inc.
    Inventor: JASDEEP MANN
  • ENGINEERED T CELLS
    Publication number: 20230044580
    Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Application
    Filed: May 7, 2020
    Publication date: February 9, 2023
    Applicants: 2SEVENTY BIO, INC., MEDIGENE IMMUNOTHERAPIES GMBH
    Inventors: JASDEEP MANN, CHRISTIAN ELLINGER, DANIEL SOMMERMEYER, BENJAMIN BOYERINAS
  • WISKOTT-ALDRICH SYNDROME GENE HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20220364123
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a human Wiskott-Aldrich syndrome gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of WAS, including but not limited to, an immune system disorder, thrombocytopenia, eczema, X-linked thrombocytopenia (XLT), or X-linked neutropenia (XLN).
    Type: Application
    Filed: April 24, 2020
    Publication date: November 17, 2022
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Joel GAY, Iram F. KHAN, Jasdeep MANN, David J. RAWLINGS, Yupeng WANG
  • PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20220340626
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: May 6, 2022
    Publication date: October 27, 2022
    Applicant: 2seventy bio, Inc.
    Inventors: Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
  • PD-1 homing endonuclease variants, compositions, and methods of use
    Patent number: 11365226
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: June 21, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Jasdeep Mann, Joel Gay, Jordan Jarjour, Joy Zhang
  • PDCD-1 HOMING ENDONUCLEASE VARIANTS
    Publication number: 20220177860
    Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 9, 2022
    Applicant: 2Seventy bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, JASDEEP MANN
  • PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210040165
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: September 8, 2017
    Publication date: February 11, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
  • BCL11A HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20190184035
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a BCL11A gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Application
    Filed: July 25, 2017
    Publication date: June 20, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Jasdeep MANN